tbuckley/cabot-search huggingface dataset:
Abstract PO-127: Single-cell liquid biopsy reveals circulating heterogeneity and converging subpopulations in relation to immunotherapy response in melanoma
Authors: Qianqian Song, Elizabeth Forbes, Lance D. Miller, Pierre L. Triozzi, Liang Liu, Wei Zhang, David R. Soto-Pantoja
Journal: Cancer Research (2020)

Abstract Though treatment with immune checkpoint blockage (ICB) has greatly improved clinical outcomes, not all patients respond to this treatment. Being able to predict which patients are likely to respond would be a significant clinical advance. Thus there remains a need for predictive biomarkers to determine in advance those with the most potential to benefit from immune checkpoint blockade. To date, most biomarkers of response are identified in tumor tissue, whereas biomarkers that can be assessed from peripheral blood are more desirable, due to the ease of access and reproducibility of sampling. To identify biomarkers associated with ICB response from peripheral blood, we apply single cell RNA sequencing to 24 peripheral blood mononuclear cell (PBMC) samples, collected from 12 stage III and IV melanoma patients before and after treatment with anti-PD1 monotherapy. Among these 12 patients, 6 are responders and 6 are non-responders. After quality control, a total of 62,273 single cells remains for further analysis. To define the cell type landscape in an unbiased manner, unsupervised clustering is used. We identify 20 robust cell clusters, including two B cell clusters (B-cell_1; B-cell_2), three myeloid clusters (monocytes, myeloid-derived suppressor cells, and M2 macrophages), twelve clusters enriched for T/NK cells, two clusters of platelets, and Hematopoietic Stem and Progenitor Cells (HSPCs). Across all patients, cell composition differs between pre- and post-treatment samples. Strikingly, responders have significant greater proportions of B-cell_1 cells in their pre-treatment samples than non-responders. At gene level, our analysis identifies an individual overexpressed marker in B-cell_1, i.e. IGLC3, which is highly enriched in responders than non-responders before treatment. In summary, our analysis identifies specific cell type and gene within patients’ PBMC samples that can serve as predictive biomarkers for patient’s response to ICB. Citation Format: Qianqian Song, Elizabeth Forbes, Lance D. Miller, Pierre L. Triozzi, Liang Liu, Wei Zhang, David R. Soto-Pantoja. Single-cell liquid biopsy reveals circulating heterogeneity and converging subpopulations in relation to immunotherapy response in melanoma [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-127.
Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds
Authors: Louise Arnold, Ray Borrow, Kathryn Riley, Talha Munir, Richard Kelly, Rachael Jones, Jeanifer Gachev, Briony Forrest, Alexandra Pike, Petra Muus, Peter Hillmen, Morag Griffin
Journal: Blood (2020)
Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival
Authors: Sandrine Niyongere, Yamini Kathari, Zeba Singh, Emily J. Vannorsdall, Ashkan Emadi, Vu Doung, Maria R. Baer
Journal: Blood (2020)
Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries
Authors: Mackenzie R. Wehner
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Improved Outcome in Pediatric AML - the AML-BFM 2012 Study
Authors: Katharina Waack, Markus Schneider, Christiane Walter, Ursula Creutzig, Jan-Henning Klusmann, Mareike Rasche, Heidrun Boztug, Katharina Jansen, Gabriele Escherich, Michael Frühwald, Michael Dworzak, Dirk Reinhardt
Journal: Blood (2020)
Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
Authors: Yoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, Wenyue Hu, Stephane Thibault, Fan Jiang, Mauricio Leal, Madan Katragadda, Andreas Maderna, Russell Dushin, Nadira Prashad, Manoj B. Charati, Tracey Clark, L. Nathan Tumey, Xingzhi Tan, Andreas Giannakou, Edward Rosfjord, Hans-Peter Gerber, Lioudmila Tchistiakova, Frank Loganzo, Christopher J. O'Donnell, Puja Sapra
Journal: Clinical Cancer Research (2020)

Mortality due to acute myeloid leukemia (AML) remains high, and the management of relapsed or refractory AML continues to be therapeutically challenging. The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has provided a proof of concept for an ADC-based therapeutic for AML. Several other ADCs have since entered clinical development of AML, but have met with limited success. We sought to develop a next-generation ADC for AML with a wide therapeutic index (TI) that overcomes the shortcomings of previous generations of ADCs.We compared the TI of our novel CD33-targeted ADC platform with other currently available CD33-targeted ADCs in preclinical models of AML. Next, using this next-generation ADC platform, we performed a head-to-head comparison of two attractive AML antigens, CD33 and CD123.Our novel ADC platform offered improved safety and TI when compared with certain currently available ADC platforms in preclinical models of AML. Differentiation between the CD33- and CD123-targeted ADCs was observed in safety studies conducted in cynomolgus monkeys. The CD33-targeted ADC produced severe hematologic toxicity, whereas minimal hematologic toxicity was observed with the CD123-targeted ADC at the same doses and exposures. The improved toxicity profile of an ADC targeting CD123 over CD33 was consistent with the more restricted expression of CD123 in normal tissues.We optimized all components of ADC design (i.e., leukemia antigen, antibody, and linker-payload) to develop an ADC that has the potential to translate into an effective new therapy against AML.
Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
Authors: Wei Wu, Alessio Bruscaggin, Alexandra Valera, Elena Flospergher, Ferdinando Bonfiglio, Valeria Spina, Lodovico Terzi-di-Bergamo, Alden Moccia, Riccardo Moia, Alessia Ruffini, Anastasios Stathis, Martin Faderl, Ricardo Koch, Gabriela Forestieri, Katia Pini, Adalgisa Condoluci, Maria Cristina Pirosa, Bernhard Gerber, Silke Gillessen, Georg Stüssi, Michele Ghielmini, Franco Cavalli, Stefano Luminari, Renzo Boldorini, Luca Mazzucchelli, Gianluca Gaidano, Davide Rossi, Emanuele Zucca
Journal: Blood (2020)
Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic
Authors: Jenny K.W. Lam, Chucky C.K. Cheung, Michael Y.T. Chow, Emily Harrop, Susie Lapwood, Stephen I.G. Barclay, Ian C.K. Wong
Journal: Advanced Drug Delivery Reviews (2020)
Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational Study
Authors: Patrick Van Dreden, Guillaume Voiriot, Alexandre Alabbadi, Ismail Elalamy, Loula Papageorgiou, Hélène Cost, Aurélie Rousseau, Matthieu Turpin, Muriel Fartoukh, Grigorios T. Gerotziafas
Journal: Blood (2020)
A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling
Authors: Gi June Min, Byung Sik Cho, Sung-Soo Park, Silvia Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Heeje Kim, Seok Lee
Journal: Blood (2020)
Brentuximab Vedotin Plus Chemotherapy As Pre-Autologous Stem Cell Transplantation Salvage Treatment in Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from Peru
Authors: Shirley Quintana, Jule F Vasquez, Lourdes Lopez, Cindy Alcarraz, Claudio Flores, Cesar Samanez-Figari
Journal: Blood (2020)
Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia
Authors: Ahmed Basha, Mohamed Izham, Anas Hamad, Prem Chandra, Nabil E Omar, Mohammad Abdul-Jaber Abdulla, Mahmood B Aldapt, Radwa M Hussein, Ahmed Mahfouz, Ahmed A Adel, Hawraa M Shwaylia, Yeslem Mohamed Aly Ekeibed, Rami AbuMousa, Mohamed A Yassin
Journal: Blood (2020)
A Phase 1/2 Study of Lentiviral-Mediated <i>Ex-Vivo</i> Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1
Authors: Donald B. Kohn, Gayatri R Rao, Elena Almarza, Dayna Terrazas, Eileen Nicoletti, Augustine Fernandes, Caroline Kuo, Satiro N. De Oliveira, Theodore B. Moore, Kenneth M Law, Brian C Beard, Julian Sevilla, Cristina Mesa-Núñez, Juan A Bueren, Jonathan D Schwartz
Journal: Blood (2020)
Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma
Authors: Alexandra M Poos, Nicola Giesen, Calogerina Catalano, Nagarajan Paramasivam, Daniel Huebschmann, Lukas John, Anja Baumann, Jason Hochhaus, Carsten Mueller-Tidow, Sandra Sauer, Stefanie Huhn, Matthias Schlesner, Benedikt Brors, Hartmut Goldschmidt, Marc S. Raab, Niels Weinhold
Journal: Blood (2020)
Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells
Authors: Kyung Hee Chang, Zoe Alaniz, Yuki Nishida, Cedric E. Dos Santos, Eric Slosberg, Naval Daver, Michael Andreeff
Journal: Blood (2020)
Abstract 470: Recording Cell Migration Dynamics in Mouse Tissues With Cells Secreting Fluorescence Protein-tagged Collagen
Authors: Zhongming Chen
Journal: Circulation Research (2020)

Background: Cell migration is an important step involved in heart regeneration and many cardiovascular diseases. However, cell migration dynamics in vivo is poorly understood due to the challenges from mammal hearts, which are opaque and fast beating, and thus individual cardiac cells cannot be imaged or tracked. Aims: In this study, cell migration dynamics in the heart is recorded with a novel strategy, in which fluorescence protein-tagged collagen is secreted from cells and deposited into extracellular matrix, forming visible trails when cells are moving in tissues. As a proof-of-concept, transplanted migration dynamics of cardiac progenitor cells in mouse hearts were investaged. Methods: Stable cell lines expressing mCherry-tagged type I collagen were generated from isolated cardiac progenitor cells, ABCG2 + CD45 - CD31 - cells (side populations), or c-kit + CD45 - CD31 - cells (c-kit + CPCs). The cell migration dynamics were monitored and measured based on the cell trails after cell transplantation into mouse tissues. Results: The stable cell lines form red cell trails both in vitro and in vivo (Fig. 1A &amp; 1B, Green: GFP; Red: mCherry-collagen I, Blue: DAPI, bar: 50 microns). In culture dishes, the cells form visible cell trails of fluorescence protein. The cell moving directions are random, with a speed of 288 +/- 79 microns/day (side populations, n=3) or 143 +/-37 microns/day (c-kit + CPCs, n=3). After transplantation into wild-type mouse hearts, the cells form highly tortuous trails along the gaps between the heart muscle fibers. Angle between a cell trail and a muscle fiber is 16+/-16 degree (n=3). Side populations migrate twice as fast as c-kit+ CPCs in the heart (16.0 +/-8.7 microns/day vs. 8.1+/-0.0 microns/day, n=3, respectively), 18 time slower than the respective speeds in vitro . Additionally, side populations migrate significantly faster in the heart than in the skeletal muscles (26.4+/-5.8 microns/day, n=3). The side populations move significantly faster in immunodeficient mouse hearts (36.7+/-13.3 microns/day, n=3, typically used for studying cell therapies) than in wild-type mouse hearts. Conclusion: For the first time, cell migration dynamics in living hearts is monitored and examined with genetically modified cell lines. This study may greatly advance the fields of cardiovascular biology.
Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis
Authors: Zhao-Lan Hu, Cong Luo, Plinio Reinaldo Hurtado, Hui Li, Shuang Wang, Bo Hu, Jun-Mei Xu, Yang Liu, Shi-Qing Feng, Ernesto Hurtado-Perez, Kang Chen, Xin-Fu Zhou, Chang-Qi Li, Ru-Ping Dai
Journal: Theranostics (2020)

Rationale: Brain-derived neurotrophic factor precursor (proBDNF) is expressed in the central nervous system (CNS) and the immune system.However, the role of proBDNF in the pathogenesis of multiple sclerosis (MS) is unknown.Methods: Peripheral blood and post-mortem brain and spinal cord specimens were obtained from multiple sclerosis patients to analyze proBDNF expression in peripheral lymphocytes and infiltrating immune cells in the lesion site.The proBDNF expression profile was also examined in the experimental autoimmune encephalomyelitis (EAE) mouse model, and polyclonal and monoclonal anti-proBDNF antibodies were used to explore their therapeutic effect in EAE.Finally, the role of proBDNF in the inflammatory immune activity of peripheral blood mononuclear cells (PBMCs) was verified in vitro experiments.Results: High proBDNF expression was detected in the circulating lymphocytes and infiltrated inflammatory cells at the lesion sites of the brain and spinal cord in MS patients.In the EAE mouse model, proBDNF was upregulated in CNS and in circulating and splenic lymphocytes.Systemic but not intracranial administration of anti-proBDNF blocking antibodies attenuated clinical scores, limited demyelination, and inhibited proinflammatory cytokines in EAE mice.Immuno-stimulants treatment increased the proBDNF release and upregulated the expression of p75 neurotrophic receptors (p75 NTR ) in lymphocytes.The monoclonal antibody against proBDNF inhibited the inflammatory response of PBMCs upon stimulations. Conclusion:The findings suggest that proBDNF from immune cells promotes the immunopathogenesis of MS.Monoclonal Ab-proB may be a promising therapeutic agent for treating MS.
COVID-19 Test Result Turnaround Time for Residents and Staff in US Nursing Homes
Authors: Brian E. McGarry, Gillian K. SteelFisher, David C. Grabowski, Michael L. Barnett
Journal: JAMA Internal Medicine (2020)

Skilled nursing facility (SNF) residents comprise over 40% of coronavirus disease 2019 (COVID-19) deaths nationally. 1 Surveillance testing is critical for controlling asymptomatic and presymptomatic viral transmission in these high-risk settings. 2r surveillance testing in SNFs to effectively guide infection control, results need to be obtained in less than 1 day. 3To facilitate such rapid testing, 4 Medicare began distributing pointof-care severe acute respiratory syndrome coronavirus 2 antigen test instruments in July 2020, focused on SNFs in COVID-19 hot spot counties. 5Little is known about the adequacy of test result turnaround in SNFs.
SAT0230 Economic analysis of rofecoxib versus nsaids: comparison across different provinces in canada
Authors: MA Marentette, C Attard, JM Pellissier, SX Kong, C Sauvageau
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> Rofecoxib (VIOXX) patients were shown in Phase III clinical trials to have significantly fewer clinically significant gastrointestinal (GI) adverse events than those who received non-selective NSAIDs for the treatment of osteoarthritis (OA). We evaluated the clinical and economic consequences of rofecoxib prescription in each of the ten Canadian provinces for patients over 65 who were assumed to have failed acetaminophen therapy. <h3>Methods</h3> A cost-effectiveness analysis was conducted comparing rofecoxib to non-selective NSAIDs with respect to their gastrointestinal effects on patients with OA. A decision analytic model, with a time horizon of one year, was constructed focussing on the event rates from a pooled analysis of 8 Phase IIb/III clinical trials. The number of perforations, ulcers and bleeds (PUBs) in each strategy was used as the primary measure of effectiveness. Province-specific inputs were incorporated to determine the relative impact of provincial differences in reimbursement policies, medication mix, prescription length, and dispensing fees on the economic results. <h3>Results</h3> In six of the ten Canadian provinces, the replacement of traditional NSAIDs with rofecoxib was associated with fewer PUBs, but at a slightly higher annual cost per patient to the provincial governments (range: $21.37 – $133.42). In Alberta, Manitoba, Quebec and Newfoundland the use of rofecoxib was associated with an annual cost saving in addition to the clinical benefit of fewer PUBs. The variation in the model results across provinces was primarily due to the variation in average NSAID and GPA costs across the provinces. As drug choices differ between the provinces, the average daily cost of an NSAID was seen to vary between $0.49 in Nova Scotia to $1.24 in Newfoundland. Likewise, the average daily cost of a GPA ranged from $0.72 in New Brunswick to $2.11 in Alberta. <h3>Conclusion</h3> Rofecoxib may represent a cost-effective alternative to non-selective NSAIDs for the treatment of OA in Canada, despite provincial differences in reimbursement policies and medication mix which generate varying burdens on payers and patients.
Analysis of the Short-Term Efficacy of Decitabine Combined with Low-Dose Cytarabine in the Treatment of JMML
Authors: Yuli Cai, Weiru Liang, Meihui Yi, Xiaoyan Zhang, Fang Liu, Lixian Chang, Ye Guo, Yumei Chen, Yao Zou, Wenyu Yang, Xiaofan Zhu
Journal: Blood (2020)
Abstract IA21: Stem cells play a role in human leukemia from origin to relapse
Authors: John E. Dick
Journal: Cancer Research (2020)

Abstract Individual cancer cells exhibit functional heterogeneity of many cancer hallmarks including the capacity for sustaining long-term clonal maintenance, a stemness property involving self-renewal. Our studies established that only rare AML cells possessed such leukemia stem cell (LSC) properties and that AML is a cellular hierarchy. LSC were found to be highly relevant to human disease as gene signatures specific to LSC were much more predictive of patient response to therapy and overall survival compared to the bulk non-LSC AML cells. We have now provided insights into how LSC develop during leukemogenesis. Through sequencing of purified populations of normal blood cells, AML cells, and xenografts from paired diagnosis/relapse AML samples, we tracked the full arc of leukemia development in humans: from the cell of origin (an HSC) that acquires the first genetic mutation; to pre-leukemic clonal expansion of HSC; the generation of genetically diverse LSC; and finally to the cellular origin of relapse (rare LSC subclones) within the diagnosis sample. Similar studies have been undertaken in B-ALL where relapse-fated subclones were found within the diagnosis sample before exposure to chemotherapy. These clones possess distinct epigenetic and metabolic properties that underlie their partially resistance to chemotherapy and they possess stemness signatures that drive their ability to regenerate relapse disease. These studies resulted in identification of novel therapeutic targets of relapse-fated subclones to begin envisioning approaches to eradicate relapse before it develops. Finally, the identification of clonally expanded pre-leukemic HSPC in the diagnosis blood sample of many AML samples predicted that it should be possible to identify individuals who are at risk for progressing to AML long before AML develops. We genotyped individuals from the general population who were enrolled in the large cohort (EPIC) who eventually developed AML and compared them to the enrollment sample of others who never progressed to AML. We have found a clear signature that is able to predict with high accuracy those individuals who have age related clonal hematopoiesis who progress to AML, almost 10 years prior to AML development. This is distinct from individuals who have benign clonal hematopoiesis who never progress. These new findings offer the potential for future intervention to permit AML prevention trials. Citation Format: John E. Dick. Stem cells play a role in human leukemia from origin to relapse [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA21.
Chemotherapy Based Salvage Regimens Are Associated with Poor Outcomes in Refractory Classical Hodgkin Lymphoma
Authors: Ashley Rose, Dakota Jenneman, Leidy Isenalumhe, Julio C. Chavez, Bijal Shah, Lubomir Sokol, Javier Pinilla Ibarz, Celeste Bello, Hayder Saeed
Journal: Blood (2020)
Disseminated Intravascular Coagulation Score Evolution in 48 Hours Predicts Early Death in Newly-Diagnosed Chemotherapy-Treated Acute Promyelocytic Leukemia Patients
Authors: Joana Brioso Infante, Graca Esteves, Helena Martins, Julia Medeiros, Daniela Alves, Conceicao Lopes, Maria Joao Costa, Maria Blanca Guerrero, Raul Moreno, Fernanda Lourenço, Carlos Martins, Joao F Lacerda, João Raposo
Journal: Blood (2020)
Low Prevalence of T-Cell Lymphoblastic Leukemia/Lymphoma in an Adult Hispanic Population: A Report of the Acute Leukemia Working Group (GTLA)
Authors: Luis Felipe Rubalcava-Lara, Emmanuel Almanza Huante, Roberta Demichelis, Juan Rangel-Patiño, Andres Gomez-De Leon, Gerardo A De la rosa-Flores, Alvaro Cabrera Garcia, katheryn Betsabe Garzon, Karla Adriana Espinosa
Journal: Blood (2020)
Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study
Authors: Nina Khanna, Maja Weisser, Anemone Hedstueck, Sarah Tschudin Sutter, Sandra Roesch, Manuel Battegay, Laura Infanti, Andreas Holbro, Michael Paul Busch, Graham Simmons, Philip Felgner, Mars Stone, Melissa von Goetz, Rafael de Assis, Saahir Khan, Jason Tsai, Peter Robinson, David Seftel, Anil Bagri, Laurence Corash, Andreas S. Buser
Journal: Blood (2020)
Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints
Authors: Luca Malcovati, Simon Crouch, Aniek O. De Graaf, Sarah Sandmann, Magnus Tobiasson, Olivier Kosmider, Bert A. van der Reijden, Daniel Painter, Arjan A. Van de Loosdrecht, Argiris Symeonidis, Jaroslav Cermak, Emmanuelle Clappier, Claude Preudhomme, Reinhard Stauder, Moshe Mittelman, Ulrich Germing, David Bowen, Pierre Fenaux, Corine Van Marrewijk, Alexandra Smith, Martin Dugas, Eva Hellstrom Lindberg, Theo M de Witte, Michaela Fontenay, Joop Jansen
Journal: Blood (2020)